This paper examines China’s transition from pharmaceutical “free rider” to global innovator over the last decade. In 2010, China accounted for less than 8% of global clinical trials; by 2020, it had surpassed the US in annual registered clinical trial volume. To study this transformation, we compile a comprehensive, synchronized database spanning the pharmaceutical drug…
The rise of China as a global innovator in pharma (incentives matter)
The rise of China as a global innovator in pharma (incentives matter)
26 Mar 2026 Leave a comment
in development economics, entrepreneurship, growth miracles, health economics Tags: drug lags
Recent Comments